Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →If you are on a GLP-1, you are in the most-targeted ad audience on the internet for peptide clinics. Every Instagram story promises something: accelerated fat loss, sleep like you were eighteen, skin you can see through, recovery that outpaces your joints. Most of it comes wrapped in the implication that the molecule is "basically like Ozempic, but for something else."
This guide is the conversation we have with GLP-1 patients who ask us, privately, whether any of it is legit. It is shorter than our academic peptide review on longevitynews.io for a reason — the question "should I stack a second peptide on top of my GLP-1?" is narrower than "what does the whole peptide world look like?" and it deserves a more direct answer.
What are peptides, briefly?
Peptides are short chains of amino acids, typically 2–50 residues long. Your body makes thousands of them: insulin (51 amino acids — technically a small protein, but often grouped with peptides), oxytocin, glucagon, GLP-1 itself. Pharmaceutical peptides either mimic endogenous hormones (semaglutide → GLP-1, tirzepatide → GLP-1 + GIP, sermorelin → growth hormone releasing hormone) or act as signaling mimetics (BPC-157, TB-500).
Peptides are small enough to be chemically synthesized rather than grown in bacteria or yeast. That makes them cheaper to produce than many biologics — but also makes them easy to counterfeit, which is why the research-chemical market for peptides is enormous.
Which peptides are actually FDA-approved for something?
The FDA-approved list is shorter than peptide marketing implies. For weight and metabolic health specifically:
| Peptide | FDA status | Use |
|---|---|---|
| Semaglutide (Ozempic, Wegovy, Rybelsus) | Approved | Type 2 diabetes / chronic weight management |
| Tirzepatide (Mounjaro, Zepbound) | Approved | Type 2 diabetes / chronic weight management |
| Liraglutide (Victoza, Saxenda) | Approved | T2D / weight management (older daily GLP-1) |
| Dulaglutide (Trulicity) | Approved | T2D |
| Tesamorelin (Egrifta) | Approved | HIV-associated lipodystrophy (visceral fat reduction) |
| Sermorelin | Approved (discontinued in US) | Growth hormone deficiency |
| PT-141 / Bremelanotide (Vyleesi) | Approved | Hypoactive sexual desire disorder (women) |
Notably absent from this list: BPC-157, TB-500, CJC-1295, Ipamorelin, Epithalon, Thymosin Alpha-1, MOTS-c, 5-Amino-1MQ, and the other peptides that dominate "peptide clinic" marketing. Those are not FDA-approved for anything. Some are legitimately compoundable under specific circumstances; others are in the research-chemical gray zone.
What's legally compoundable vs. research-only in 2026?
In late 2023 the FDA reclassified a set of peptides onto "Category 2" of its bulk drug substances list — meaning the agency has significant safety concerns and they should not be used in bulk compounding by 503A pharmacies. The notable Category 2 entrants were:
- BPC-157 (Body Protection Compound-157)
- Thymosin Beta-4 / TB-500
- CJC-1295 (with or without DAC)
- Ipamorelin
- Selank, Semax, Epithalon — several nootropic/sleep peptides
The practical effect: most licensed U.S. 503A pharmacies stopped compounding these peptides in bulk. Some may still dispense patient-specifically under state-level patient-specific compounding rules, but "subscription monthly delivery" of these peptides through a clinic is a clear sign that the operation is either operating in a gray area or sourcing from research-chemical suppliers dressed up as pharmacies.
Meanwhile, several peptides remain squarely legitimate: tesamorelin (approved), sermorelin (compounded as a legitimate option at some 503A pharmacies under patient-specific scripts), PT-141, and experimental next-generation GLP-1-family molecules like retatrutide (a triple GLP-1/GIP/glucagon agonist in late-stage trials, not yet approved). See our compounded GLP-1 guide for what a legitimate compounding pharmacy looks like.
The peptides GLP-1 patients ask about most
BPC-157
Marketed for: joint recovery, gut healing, tendon repair. What's real: promising results in rodent studies. What's missing: any rigorous human trial. 2026 status: FDA Category 2. Sold primarily as a research chemical. Our clinical take: we do not recommend adding this to a GLP-1 protocol. If you have a tendon issue, see a sports-medicine physician.
CJC-1295 / Ipamorelin (GH-releasing peptides)
Marketed for: sleep, body composition, recovery, "anti-aging." What's real: they do increase growth hormone and IGF-1 in the short term. What's missing: outcomes data, long-term safety, and a clear answer to why most patients are chasing growth hormone at all. 2026 status: Category 2. If you are interested in growth hormone physiology, your primary care doctor can order IGF-1, GHBP, and a dynamic GH test first — most people chasing GH through peptides do not actually have low GH.
TB-500 / Thymosin Beta-4
Marketed for: injury recovery, wound healing, hair growth. What's real: animal models show tissue-repair effects. Humans: limited trial data. 2026 status: Category 2. Our take: similar to BPC-157 — interesting biology, not ready for clinical use outside of research settings.
Tesamorelin
Marketed for: visceral fat reduction. What's real: this is an FDA-approved peptide for HIV-associated lipodystrophy with solid visceral-fat-reduction data. Off-label use in non-HIV patients: happens, usually via 503A. Some small trials in NAFLD and general visceral adiposity. Our take for a GLP-1 patient: a GLP-1 already reduces visceral fat significantly. Adding tesamorelin is a lot of money for marginal benefit in most patients. Worth discussing with a specialist if you have specific visceral-fat targets after GLP-1.
PT-141 (Bremelanotide)
Marketed for: sexual desire / libido. What's real: FDA-approved (as Vyleesi) for women with hypoactive sexual desire disorder. Sometimes prescribed off-label for men. Our take: legitimate product with a narrow indication. Not a general "wellness" peptide.
Retatrutide (next-generation GLP-1-family)
Status: not FDA-approved as of April 2026; late-phase trials have shown ~24% mean weight loss at 48 weeks, which would be the highest yet seen in this class. Our take: worth watching. Anyone offering it now is doing so outside the regulatory system. Wait for approval — it is likely coming in 2026–2027.
3-min quiz
Curious what's actually in your GLP-1 program?
Chia only uses FDA-approved molecules (semaglutide, tirzepatide) from licensed U.S. pharmacies. No experimental peptides. No research chemicals.
Should I stack another peptide on top of my GLP-1?
The honest answer in April 2026: for the overwhelming majority of GLP-1 patients, no. Not because peptide biology is fake, but because the risk/benefit math rarely works out:
- GLP-1s are already producing 15–20% weight loss, visceral-fat reduction, cardiovascular benefit, improved insulin sensitivity, and better sleep quality for many patients. That's a lot of biological bandwidth already in use.
- Most "add-on" peptides lack rigorous human trial data showing additional benefit on top of a GLP-1.
- Quality control on non-FDA-approved peptides is highly variable. You are stacking a reliable drug with a less reliable one.
- Price adds up. A legitimate GLP-1 costs $200–$1,350/month. Stacking 2–3 additional peptides often doubles that.
- If you are stalling on GLP-1 weight loss, the evidence-based answer is usually a dose or molecule change (see the plateau guide) — not a second peptide.
Exceptions we do see: patients with specific clinical indications (e.g., tesamorelin in someone with persistent visceral fat after GLP-1 max dose, PT-141 for an approved libido indication). Those are narrow, specialist-managed cases. They are not the same as buying a three-peptide "optimization stack" off a clinic's shopping cart.
Red flags when evaluating a peptide clinic
- "Research use only" labels, period.
- No licensed prescribing clinician named, or the "clinician" is a single name with no verifiable license.
- Sells peptides that are on FDA Category 2 as monthly subscriptions.
- Ships from outside the US or uses no cold-chain packaging.
- Claims efficacy backed only by testimonials or social media videos.
- Bundles GLP-1s with "performance" peptides into a single package without any intake or clinical review.
- Aggressive dose escalation without any monitoring.
- No PCAB or 503B certification and no state pharmacy license number.
Frequently asked questions
It's not FDA-approved for any use, and it's on the FDA's Category 2 list for bulk compounding. Some 503A pharmacies may still dispense it patient-specifically in narrow situations, but most "BPC-157 clinics" are operating in a gray zone or selling research chemicals. Not something we recommend.
Possible, but the medical case for it is specific. If you have a documented growth hormone deficiency or a specific clinical indication, a specialist can prescribe. In a generally healthy adult whose weight loss is going well, the upside is small and the cost is not.
Retatrutide is the most exciting next-generation molecule in the GLP-1 family. It's a triple agonist (GLP-1 + GIP + glucagon) showing ~24% mean weight loss in phase-3 trials — higher than tirzepatide. It's not FDA-approved yet. We expect approval in 2026–2027. Anyone selling it as a compounded product today is stepping ahead of the regulatory system.
Not inherently. "Peptide" is a molecular class, not a safety rating. Approved peptide drugs are held to the same standards as any other medication. Unapproved peptides sold as research chemicals are categorically riskier because they have no regulatory oversight.
Legally questionable and practically unsafe. Imported peptides often fail potency testing, sometimes contain different molecules than labeled, and have no chain of custody. We would not inject any of them.
Epithalon has interesting cell-biology research but no rigorous human outcome trials. It's on FDA Category 2. Currently sold primarily through research-chemical channels. We would not recommend it to a patient.
No. The longevitynews.io piece is a broader academic review for general readers. This one is a focused patient-perspective guide specifically for people already on GLP-1 therapy. Different structure, different depth, narrower recommendations.
Bottom line
Peptides as a class are not snake oil. A handful of peptide drugs are genuinely life-changing — your GLP-1 is the most obvious example. But most of what gets marketed to GLP-1 patients as "peptide therapy" is either research-chemical territory or commercially optimistic spin on biology that has not been validated in human trials. For the vast majority of patients, your GLP-1 is already doing the heavy lifting on weight, inflammation, cardiometabolic risk, and food noise. Additional peptides are rarely the unlock they are marketed as.
If you are still curious, do the one non-negotiable thing: work with a licensed clinician at a legitimate pharmacy, and stay away from anything labeled "research use only." That principle alone will keep you out of the worst of this market.
References
- 1.FDA. Bulk Drug Substances Nominated for Use in Compounding — Category 2 list update (2023).
- 2.Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
- 3.Falutz J, et al. Tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat. N Engl J Med. 2007;357:2359-2370.
- 4.FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (updated 2025).
- 5.Pharmacy Compounding Accreditation Board (PCAB) — Accreditation standards.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
